AR047340A1 - Derivados de triazol como antagonistas del receptor vi a - Google Patents
Derivados de triazol como antagonistas del receptor vi aInfo
- Publication number
- AR047340A1 AR047340A1 ARP040104826A ARP040104826A AR047340A1 AR 047340 A1 AR047340 A1 AR 047340A1 AR P040104826 A ARP040104826 A AR P040104826A AR P040104826 A ARP040104826 A AR P040104826A AR 047340 A1 AR047340 A1 AR 047340A1
- Authority
- AR
- Argentina
- Prior art keywords
- saturated
- optionally substituted
- ring
- heterocyclic ring
- number chosen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Abstract
Un compuesto de formula (1) o derivados del mismo aceptables farmacéuticamente, en el que: X representa -[CH2]a-R o -[CH2]a-O-[CH2]b-R; a representa un numero elegido entre 0 y 6; b representa un numero elegido entre 0 y 6; R representa H, CF3 o Het; Het representa un anillo heterocíclico de 5 o 6 miembros, saturado, parcialmente saturado o aromático; Y representa uno o más sustituyentes elegidos independientemente entre -[O]c-[CH2]d-R1, que pueden ser iguales o diferentes en cada aparicion; c en cada aparicion representa independientemente un numero elegido entre 0 o 1; d en cada aparicion representa independientemente un numero elegido entre 0 y 6; R1 en cada aparicion representa independientemente H, halo, CF3, CN o Het1; Het1en cada aparicion representa independientemente un anillo heterocíclico insaturado de 5 o 6 miembros; V representa un enlace directo o -O-; el anillo A representa un anillo heterocíclico saturado de 5 a 7 miembros, o un grupo fenileno; Q representa un enlace directo o -N(R2)-; R2 representa H o alquilo C1-6; Z representa -[O]e-[CH2]f-R3, un anillo fenilo (opcionalmente fusionado con un anillo de benceno o Het2, y además siendo el grupo en su conjunto opcionalmente sustituido), o Het 3 (opcionalmente fusionado con un anillo de benceno o Het4, y además siendo el grupo en su conjunto un grupo opcionalmente sustituido); R3 representa alquilo C1-6 (opcionalmente sustituido), cicloalquilo C3-6, cicloalquenilo C3-6, fenilo (opcionalmente sustituido), Het5 o NR4R5; e representa un numero elegido entre 0 o 1; f representa un numero elegido entre 0 y 6; Het2 y Het5 representan independientemente anillos heterocíclicos saturados, parcialmente saturados o aromáticos, de 5 o 6 miembros; Het3 representa un anillo heterocíclico saturado, parcialmente saturado o aromático de 4 o 6 miembros; Het4 representa un anillo heterocíclico aromático de 6 miembros, opcionalmente sustituido; R4 y R5 representan independientemente alquilo C1-6, alquiloxi C1-6, cicloalquilo C3-8 (opcionalmente fusionado con cicloalquilo C3-8), Het6 o ; Het6 representa un anillo heterocíclico saturado, parcialmente saturado o aromático de 5 o 6 miembros opcionalmente sustituido; son utiles para tratar un trastorno para el cual está indicado un antagonista de V1a, en particular la dismenorrea.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0329693A GB0329693D0 (en) | 2003-12-22 | 2003-12-22 | Compounds useful in therapy |
GB0408789A GB0408789D0 (en) | 2004-04-20 | 2004-04-20 | Triazole derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
AR047340A1 true AR047340A1 (es) | 2006-01-18 |
Family
ID=34740750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040104826A AR047340A1 (es) | 2003-12-22 | 2004-12-21 | Derivados de triazol como antagonistas del receptor vi a |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1701959A1 (es) |
JP (1) | JP4698604B2 (es) |
KR (1) | KR100854872B1 (es) |
AP (1) | AP2331A (es) |
AR (1) | AR047340A1 (es) |
AU (1) | AU2004309164B2 (es) |
BR (1) | BRPI0417267A (es) |
CA (1) | CA2551038C (es) |
CR (1) | CR8481A (es) |
DO (1) | DOP2004001062A (es) |
EA (1) | EA010132B1 (es) |
EC (1) | ECSP066647A (es) |
GE (1) | GEP20084571B (es) |
HK (1) | HK1095822A1 (es) |
IL (1) | IL176349A (es) |
IS (1) | IS8472A (es) |
MA (1) | MA28393B1 (es) |
NL (1) | NL1027833C2 (es) |
NO (1) | NO20063380L (es) |
OA (1) | OA13347A (es) |
PA (1) | PA8620501A1 (es) |
PE (1) | PE20051051A1 (es) |
TW (1) | TWI287541B (es) |
UY (1) | UY28693A1 (es) |
WO (1) | WO2005063754A1 (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7667041B2 (en) | 2004-05-26 | 2010-02-23 | Eisai R&D Management Co., Ltd. | Cinnamide compound |
JP5043668B2 (ja) | 2004-09-20 | 2012-10-10 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
MX2007003327A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. |
TW200626154A (en) * | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
JP5149009B2 (ja) | 2004-09-20 | 2013-02-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−CoAデサチュラーゼを阻害するためのピリダジン誘導体 |
MX2007003332A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
BRPI0515483A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase |
EP1804799B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
US7923563B2 (en) | 2004-10-26 | 2011-04-12 | Eisai R&D Management Co., Ltd. | Amorphous object of cinnamide compound |
AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
MX2007015216A (es) | 2005-06-03 | 2008-02-22 | Xenon Pharmaceuticals Inc | Derivados de aminotiazol y sus usos como agentes terapeuticos. |
EP1917255A2 (en) * | 2005-07-29 | 2008-05-07 | F. Hoffmann-Roche AG | Indol-3-yl-carbonyl-piperidin and piperazin derivatives |
TWI370130B (en) | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
WO2008013622A2 (en) * | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
US9090604B2 (en) | 2006-07-27 | 2015-07-28 | E I Du Pont De Nemours And Company | Fungicidal azocyclic amides |
AR062095A1 (es) | 2006-07-28 | 2008-10-15 | Eisai R&D Man Co Ltd | Profarmaco de compuesto cinamida |
AU2007329066B2 (en) * | 2006-12-07 | 2012-04-12 | F. Hoffmann-La Roche Ag | Spiro-piperidine derivatives |
WO2008068185A1 (en) * | 2006-12-07 | 2008-06-12 | F. Hoffmann-La Roche Ag | Spiro-piperidine derivatives as via receptor antagonists |
US7501432B2 (en) * | 2006-12-22 | 2009-03-10 | Hoffman-La Roche Inc. | Spiro-piperidine derivatives |
ATE486877T1 (de) * | 2006-12-29 | 2010-11-15 | Hoffmann La Roche | Azaspiroderivate |
CL2008000582A1 (es) | 2007-02-28 | 2008-06-27 | Eisai R&D Man Co Ltd | Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis. |
US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
TW200916469A (en) | 2007-08-31 | 2009-04-16 | Eisai R & Amp D Man Co Ltd | Multi-cyclic compounds |
EP2358202B1 (en) * | 2008-11-03 | 2016-06-15 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
EP2623499B1 (en) | 2010-10-01 | 2015-04-22 | Taisho Pharmaceutical Co., Ltd | 1,2,4-triazolone derivative |
US9447025B2 (en) | 2013-03-14 | 2016-09-20 | Kalyra Pharmaceuticals, Inc. | Bicyclic analgesic compounds |
CN105814013A (zh) | 2013-12-12 | 2016-07-27 | 卡利拉制药公司 | 双环烷基化合物及合成 |
JP6741343B2 (ja) | 2014-03-07 | 2020-08-19 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | プロペラン誘導体および合成 |
JP6833677B2 (ja) * | 2014-09-17 | 2021-02-24 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 二環式化合物 |
US10138236B2 (en) | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
MA40893B1 (fr) * | 2014-11-03 | 2018-11-30 | Bayer Pharma AG | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées |
RU2637101C2 (ru) * | 2016-01-11 | 2017-11-29 | Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр вирусологии и микробиологии" (ФГБНУ ФИЦВиМ) | Устройство для определения аспирированной дозы аэрозолей |
EP3419626A1 (en) * | 2016-02-23 | 2019-01-02 | Servicio Andaluz De Salud | Piperazine derivatives as antiviral agents with increased therapeutic activity |
AR108263A1 (es) | 2016-05-03 | 2018-08-01 | Bayer Pharma AG | Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo |
US10525041B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Pharma Aktiengesellschaft | Fluoroalkyl-substituted aryltriazole derivatives and uses thereof |
US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
EP3452457B1 (en) | 2016-05-03 | 2020-03-18 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
US20190119251A1 (en) | 2016-05-03 | 2019-04-25 | Bayer Pharma Aktiengesellschaft | Amide-substituted aryltriazole derivatives and uses thereof |
WO2017191114A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
JP6710273B2 (ja) * | 2016-05-09 | 2020-06-17 | 日本曹達株式会社 | 環状アミン化合物および有害生物防除剤 |
US10927098B2 (en) | 2016-10-20 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted triazole derivatives and uses thereof |
CA3063729A1 (en) | 2017-05-15 | 2018-11-22 | Recurium Ip Holdings, Llc | Analgesic compounds |
WO2019081291A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
WO2019081306A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
US11149023B2 (en) | 2017-10-24 | 2021-10-19 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
CA3084308A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
AU2018356352A1 (en) | 2017-10-24 | 2020-04-16 | Bayer Aktiengesellschaft | Prodrugs of substituted triazole derivatives and uses thereof |
CA3084411A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
CA3079770A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Amine substituted triazole derivatives and uses thereof |
HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素V1a受體拮抗劑之三環化合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4481360A (en) * | 1983-08-26 | 1984-11-06 | The Upjohn Company | 4H-1,2,4-Triazol-3-yl compounds |
WO2001058880A1 (fr) * | 2000-02-08 | 2001-08-16 | Yamanouchi Pharmaceutical Co., Ltd. | Derives de triazole |
CA2409819C (en) * | 2000-05-19 | 2009-09-15 | Yamanouchi Pharmaceutical Co., Ltd. | Triazole derivatives |
-
2004
- 2004-12-09 EA EA200600925A patent/EA010132B1/ru not_active IP Right Cessation
- 2004-12-09 BR BRPI0417267-1A patent/BRPI0417267A/pt active Search and Examination
- 2004-12-09 JP JP2006546356A patent/JP4698604B2/ja not_active Expired - Fee Related
- 2004-12-09 GE GEAP20049469A patent/GEP20084571B/en unknown
- 2004-12-09 AP AP2006003631A patent/AP2331A/xx active
- 2004-12-09 OA OA1200600206A patent/OA13347A/en unknown
- 2004-12-09 KR KR1020067012328A patent/KR100854872B1/ko not_active IP Right Cessation
- 2004-12-09 AU AU2004309164A patent/AU2004309164B2/en not_active Ceased
- 2004-12-09 WO PCT/IB2004/004059 patent/WO2005063754A1/en active Application Filing
- 2004-12-09 CA CA2551038A patent/CA2551038C/en not_active Expired - Fee Related
- 2004-12-09 EP EP04801354A patent/EP1701959A1/en not_active Withdrawn
- 2004-12-17 TW TW093139507A patent/TWI287541B/zh active
- 2004-12-21 UY UY28693A patent/UY28693A1/es unknown
- 2004-12-21 NL NL1027833A patent/NL1027833C2/nl not_active IP Right Cessation
- 2004-12-21 AR ARP040104826A patent/AR047340A1/es not_active Application Discontinuation
- 2004-12-22 DO DO2004001062A patent/DOP2004001062A/es unknown
- 2004-12-22 PA PA20048620501A patent/PA8620501A1/es unknown
-
2005
- 2005-01-03 PE PE2005000032A patent/PE20051051A1/es not_active Application Discontinuation
-
2006
- 2006-05-18 IS IS8472A patent/IS8472A/is unknown
- 2006-06-15 IL IL176349A patent/IL176349A/en not_active IP Right Cessation
- 2006-06-15 EC EC2006006647A patent/ECSP066647A/es unknown
- 2006-06-22 CR CR8481A patent/CR8481A/es not_active Application Discontinuation
- 2006-06-22 MA MA29125A patent/MA28393B1/fr unknown
- 2006-07-21 NO NO20063380A patent/NO20063380L/no not_active Application Discontinuation
-
2007
- 2007-03-20 HK HK07102965.0A patent/HK1095822A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1095822A1 (en) | 2007-07-06 |
BRPI0417267A (pt) | 2007-04-17 |
NL1027833A1 (nl) | 2005-06-23 |
JP4698604B2 (ja) | 2011-06-08 |
CR8481A (es) | 2007-12-04 |
NO20063380L (no) | 2006-09-22 |
PA8620501A1 (es) | 2005-08-04 |
DOP2004001062A (es) | 2005-06-30 |
KR20060101546A (ko) | 2006-09-25 |
IS8472A (is) | 2006-05-18 |
JP2007515468A (ja) | 2007-06-14 |
TW200528099A (en) | 2005-09-01 |
CA2551038A1 (en) | 2005-07-14 |
TWI287541B (en) | 2007-10-01 |
EA200600925A1 (ru) | 2006-12-29 |
AP2006003631A0 (en) | 2006-06-30 |
EP1701959A1 (en) | 2006-09-20 |
MA28393B1 (fr) | 2007-01-02 |
AU2004309164B2 (en) | 2007-11-15 |
ECSP066647A (es) | 2006-10-25 |
EA010132B1 (ru) | 2008-06-30 |
IL176349A (en) | 2011-11-30 |
GEP20084571B (en) | 2008-12-25 |
AU2004309164A1 (en) | 2005-07-14 |
CA2551038C (en) | 2010-04-27 |
WO2005063754A1 (en) | 2005-07-14 |
KR100854872B1 (ko) | 2008-08-28 |
OA13347A (en) | 2007-04-13 |
AP2331A (en) | 2011-12-05 |
UY28693A1 (es) | 2005-07-29 |
PE20051051A1 (es) | 2005-12-17 |
NL1027833C2 (nl) | 2006-03-06 |
IL176349A0 (en) | 2006-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR047340A1 (es) | Derivados de triazol como antagonistas del receptor vi a | |
AR030762A1 (es) | Piridinilamidas e imidas para usar como fungicidas | |
MY137522A (en) | Novel anti-inflammatory androstane derivatives. | |
AR010651A1 (es) | Un compuesto amina biciclico; una composicion insecticida, acaricida o nematocida que lo contiene; un metodo para combatir y controlar plagas de insectos, acaros o nematodos empleando dicho compuesto o composicion; y un metodo para preparar dicho compuesto | |
NO20052469L (no) | Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2. | |
AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
MX2021007473A (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos. | |
NO20063446L (no) | Tiazolderivater | |
AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
UY27522A1 (es) | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares | |
AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
PE20060483A1 (es) | Compuestos heterociclicos como antagonistas de nk1 | |
DE3467348D1 (de) | N-(2-nitrophenyl)-4-aminopyrimidine derivatives as microbicides | |
GB0505930D0 (en) | 2,5-Diamino substituted azo dyes | |
EA201890539A1 (ru) | Соединения пиперидинобензодиазепина, обладающие антипролиферативной активностью | |
AR015528A1 (es) | Compuestos heterociclicos como inhibidores de enzimas rotamasas, composiciones, su uso para la preparacion de medicinas, proceso para su preparacion ycompuestos intermediarios | |
CO2022003062A2 (es) | Compuestos heterocíclicos | |
MX2021007475A (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos. | |
WO1999047132A3 (en) | Heterocyclic compounds, their production and use as tachykinin receptor antagonists | |
ES2107505T3 (es) | Derivados de bencimidazol, un metodo para producirlo, fungicidas agricolas y horticolas que lo contienen como ingrediente activo y compuestos intermedios en su preparacion. | |
ECSP034891A (es) | Derivados de benzoxazepina y su uso como estimula_ dores de receptores ampa | |
CO5031336A1 (es) | Mezclas fungicidas que contienen carbamatos y un derivado aromatico | |
ATE311852T1 (de) | Färbemittel enthaltend diaminopyrazole und kationische verbindungen als oxidationsmittel und einen kuppler | |
AR040571A1 (es) | Derivados de aciloxipirrolidina, su preparacion y su aplicacion en terapeutica | |
AR073708A1 (es) | Compuestos intermediarios de tiazolil -pirazolopirimidina y procesos sinteticos que los incluyen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |